|1.||Day, Robert M: 6 articles (01/2016 - 08/2012)|
|2.||Tencer, T: 6 articles (11/2015 - 11/2015)|
|3.||Schett, Georg: 6 articles (09/2015 - 10/2010)|
|4.||Stevens, Randall M: 6 articles (07/2015 - 10/2010)|
|5.||Hu, ChiaChi: 5 articles (07/2015 - 08/2012)|
|6.||Capri, S: 4 articles (11/2015 - 11/2015)|
|7.||Caloto, T: 4 articles (11/2015 - 11/2015)|
|8.||Oskar, B: 4 articles (11/2015 - 11/2015)|
|9.||Barbieri, M: 4 articles (11/2015 - 11/2015)|
|10.||Kavanaugh, Arthur: 4 articles (06/2015 - 01/2014)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
05/01/2015 - "Studies show that treatment with apremilast results in significant improvement in both skin psoriasis and PsA symptoms. "
03/01/2012 - "Apremilast was minimally effective in AD and ACD and results were inferior to previous trials of apremilast in psoriasis."
12/01/2015 - "Apremilast was effective in the treatment of moderate-to-severe plaque psoriasis over 52 weeks."
08/01/2015 - "Both new oral medications, apremilast and tofacitinib, appear to be effective in treating psoriasis"
07/01/2015 - "Apremilast was effective in moderate to severe plaque psoriasis."
06/01/2014 - "Apremilast was effective in the treatment of psoriatic arthritis, improving signs and symptoms and physical function. "
12/01/2015 - "One phase II and four phase III clinical trials as well as long-term extension studies showed significant and sustained clinical efficacy and an adequate safety profile for apremilast in patients with active psoriatic arthritis. "
07/01/2013 - "Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study."
10/01/2012 - "Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study."
12/01/2015 - "Apremilast for the treatment of psoriatic arthritis."
|3.||Atopic Dermatitis (Atopic Eczema)
03/01/2012 - "A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis."
08/01/2012 - "These results support further development of apremilast for treatment of atopic dermatitis. "
08/01/2012 - "This investigator-initiated, open-label pilot study evaluated 2 doses of apremilast in patients with atopic dermatitis. "
08/01/2012 - "A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults."
08/01/2012 - "To investigate the preliminary safety and efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, for atopic dermatitis. "
|4.||Asthma (Bronchial Asthma)
05/01/2010 - "In addition, GlaxoSmithKline plc is developing 256066, an inhaled formulation of a PDE4 inhibitor that has demonstrated efficacy in trials in asthma, and apremilast from Celgene Corp has been reported to be effective for the treatment of psoriasis. "
05/01/2005 - "CC-10004, a phosphodiesterase 4 inhibitor and selective cytokine inhibitor, is under development by Celgene for the potential treatment of asthma, chronic obstructive pulmonary disease, inflammation and psoriasis. "
01/01/2011 - "The path from an early, pioneering study with Ro20-1724 showing reduction of psoriatric plaque size in 1979 to modern PDE4 inhibitors such as oral apremilast in development for psoriasis, the inhaled PDE4 inhibitor GSK256066 in development for asthma and COPD and finally roflumilast, the first PDE4 inhibitor approved and currently marketed as an oral, once-daily remedy for severe COPD was marked by large progress in chemical optimization based on improved understanding of PDE4 biology and drug-like properties determining the appropriate pharmacokinetic profile. "
05/01/2014 - "The efficacy and safety evaluations of several PDE4 inhibitors are currently carried on in clinical trials, for example GSK256066 in asthma, roflumilast and GSK256066 in chronic obstructive pulmonary disease, tetomilast in inflammatory bowel disease, and apremilast in dermatitis and arthritis etc. This article reviews the recent progress on PDE4-targeted therapy for inflammatory diseases. "
08/01/2012 - "The group receiving apremilast, 20 mg twice daily, displayed a significant reduction from baseline of pruritus (P=.02) and the DLQI (P=.003) at 3 months. "
12/01/2015 - "Patients treated with apremilast showed significant improvements in quality of life (as assessed by the Dermatology Life Quality Index) and pruritus at week 16 compared with placebo (P < 0·001). "
01/01/2013 - "Greater improvements from baseline in pruritus VAS scores were reported with apremilast 20 (-35.5%) and 30 mg BID (-43.7%) versus placebo (-6.1%; P≤0.005). "
01/01/2013 - "Apremilast treatment resulted in improved HRQOL, including DLQI and pruritus VAS over 16 weeks of treatment, in patients with moderate to severe psoriasis."
|1.||Phosphodiesterase 4 Inhibitors
|2.||Type 4 Cyclic Nucleotide Phosphodiesterases
|4.||6- ((3- ((dimethylamino)carbonyl)phenyl)sulfonyl)- 8- methyl- 4- ((3- methyloxyphenyl)amino)- 3- quinolinecarboxamide
|6.||Interleukin-23 (Interleukin 23)
|8.||Interleukin-12 (IL 12)